Could GLUT12 be a potential therapeutic target in cancer treatment? A preliminary report

Journal of Cancer

Volumn 6, Issue 2, 2015, Pages 139-143

  Pujol Gimenez, Jonai ^a   de Heredia, Fátima Pérez ^b   Idoate, Miguel Angel ^c   Airley, Rachel ^d   Lostao, María Pilar ^a   Evans, Andrew Robert ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Cancer cell lines; GLUT12; Glycolytic metabolism; Immunohistochemistry; Spheroid

Indexed keywords

GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 12; GLUCOSE TRANSPORTER 3; UNCLASSIFIED DRUG;

ANAEROBIC METABOLISM; ARTICLE; CANCER CELL LINE; CANCER THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; TUMOR SPHEROID;

EID: 84920934675     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.10429     Document Type: Article

References (25)

1. Ostergaard L, Tietze A, Nielsen T, et al. The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res. 2013; 73: 5618-5624. Doi:10.1158/0008-5472.CAN-13-0964 [doi].
2. Uldry M and Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 2004; 447: 480-489. Doi:10.1007/s00424-003-1085-0
3. Medina RA and Owen GI. Glucose transporters: expression, regulation and cancer. Biol.Res. 2002; 35: 9-26.
4. Szablewski L. Expression of glucose transporters in cancers. Biochim. Biophys.Acta. 2013; 1835: 164-169. Doi:10.1016/j.bbcan.2012.12.004; 10.1016/j.bbcan.2012.12.004.
5. Godoy A, Ulloa V, Rodriguez F, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J.Cell.Physiol. 2006; 207: 614-627. Doi:10.1002/jcp.20606.
6. Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology. 1999; 46: 2683-2689.
7. Evans A, Bates V, Troy H, et al. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother. Pharmacol. 2008; 61: 377-393. Doi:10.1007/s00280-007-0480-1.
8. Airley RE, Phillips RM, Evans AE, et al. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int.J.Oncol. 2005; 26: 1477-1484.
9. Airley R, Evans A, Mobasheri A and Hewitt SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Ann.Anat. 2010; 192: 133-138. Doi:10.1016/j.aanat.2010.03.001 [doi].
10. Pujol-Gimenez J, Barrenetxe J, Gonzalez-Muniesa P and Lostao MP. The facilitative glucose transporter GLUT12: what do we know and what would we like to know? J.Physiol.Biochem. 2013; 69: 325-333. Doi:10.1007/s13105-012-0213-8; 10.1007/s13105-012-0213-8.
11. Stockhammer F, von Deimling A, Synowitz M, Blechschmidt C and van Landeghem FKH. Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. Journal of Molecular Histology. 2008; 39: 553-560. Doi:10.1007/s10735-008-9191-0 ER.
12. Zawacka-Pankau J, Grinkevich VV, Hunten S, et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J.Biol.Chem. 2011; 286: 41600-41615. Doi:10.1074/jbc.M111.240812.
13. Pujol-Gimenez J, Martisova E, Perez-Mediavilla A, Lostao MP and Ramirez MJ. Expression of the Glucose Transporter GLUT12 in Alzheimer's Disease Patients. J.Alzheimers Dis. 2014; Doi:X4382H2G3163W276 [pii].
14. Rogers S, Macheda ML, Docherty SE, et al. Identification of a novel glucose transporter-like protein-GLUT-12. Am.J.Physiol.Endocrinol.Metab. 2002; 282: E733-8.
15. Suganuma N, Segade F, Matsuzu K and Bowden DW. Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU Int. 2007; 99: 1143-1149. Doi:10.1111/j.1464-410X.2007.06765.x ER.
16. Younes M, Lechago LV, Somoano JR, Mosharaf M and Lechago J. Immunohistochemical detection of Glut3 in human tumors and normal tissues. Anticancer Res. 1997; 17: 2747-2750.
17. Zamora-Leon SP, Golde DW, Concha II, et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc.Natl.Acad.Sci.U.S.A. 1996; 93: 1847-1852.
18. Gude NM, Stevenson JL, Rogers S, et al. GLUT12 expression in human placenta in first trimester and term. Placenta. 2003; 24: 566-570. Doi:10.1053/plac.2002.0925 ER.
19. Macheda ML, Williams ED, Best JD, Wlodek ME and Rogers S. Expression and localisation of GLUT1 and GLUT12 glucose transporters in the pregnant and lactating rat mammary gland. Cell Tissue Res. 2003; 311: 91-97. Doi:10.1007/s00441-002-0661-5.
20. Gude NM, Stevenson JL, Murthi P, et al. Expression of GLUT12 in the fetal membranes of the human placenta. Placenta. 2005; 26: 67-72. Doi:10.1016/j.placenta.2004.04.006 ER.
21. Hamilton G. Multicellular spheroids as an in vitro tumor model. Cancer Lett. 1998; 131: 29-34.
22. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W and Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J.Biotechnol. 2010; 148: 3-15. Doi:10.1016/j.jbiotec.2010.01.012; 10.1016/j.jbiotec.2010.01.012.
23. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57: 4285-4300.
24. Canner JA, Sobo M, Ball S, et al. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br.J.Cancer. 2009; 101: 774-781. Doi:10.1038/sj.bjc.6605199 [doi].
25. Tweddle DA, Malcolm AJ, Cole M, Pearson AD and Lunec J. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am.J.Pathol. 2001; 158: 2067-2077. Doi:S0002-9440(10)64678-0 [pii].